GALLIPRANT^®, an EP4 receptor antagonist, is now available in the EU as a drug for the treatment of pain associated with osteoarthritis in dogs. GALLIPRANT^® was developed by Aratana Therapeutics in EU and its marketing authorization was allowed in January 2018. Elanco sells GALLIPRANT^® in EU countries. In the US, GALLIPRANT^® is second in market share (approximately 15%) within the competitive NSAID market and dispensed by more clinics than any other oral NSAID.